Clinical Trials Browser

Interventional × Carcinoma, Renal Cell × GSK 1363089 × Clear all

NCT00726323 2017-12-11

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Phase 2 Completed

74 enrolled 14 charts

Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell